ReViral’s Phase 2a RSV Study publication selected as Editor’s Pick in February 2020 issue of ASM’s Antimicrobial Agents and Chemotherapy
London, UK, January 27, 2020 –
See full published article: https://aac.asm.org/content/64/2/e01884-19
A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein.
For media inquiries, please contact:
Irma Gomez-Dib (US) +1 212 850 5761
Simon Conway (UK) +44 20 3727 1000
For investor inquiries, please contact:
T: +1 339 970 2846
Notes to Editors
ReViral is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing anti- viral therapeutics that target respiratory syncytial virus (RSV). Founded in 2011, ReViral has an experienced R&D leadership team with a successful track record in antiviral drug discovery and development. The company has developed a novel antiviral programme targeting RSV fusion with highly potent, orally bioavailable inhibitors, strong drug-like characteristics and good pharmacokinetic properties offering versatility in the route of administration. The lead candidate, sisunatovir, completed a Phase 2a study in adult volunteers, showing high potency and was well tolerated. The company also has an RSV replication programme at an earlier stage of development and plans to expand its pipeline. In July 2018, ReViral completed a $55 million Series B funding round from a group of leading venture capital investors jointly led by New Leaf Venture Partners and Novo Ventures, part of Novo Holdings A/S, with additional new investment from Perceptive Advisors. Existing investors Andera Partners, OrbiMed Advisors and Brace Pharma Capital also participated in the fundraising.
Sisunatovir is an orally administered fusion inhibitor designed to treat RSV. Sisunatovir is designed to block RSV replication by inhibiting RSV F-mediated fusion of RSV with the host cell. Preclinical tests showed sisunatovir to have an excellent toxicity profile with an attractive therapeutic index. In Phase 1 clinical studies, sisunatovir showed excellent exposure with no serious adverse events being reported. In 2018, we reported results from a Phase 2a
challenge study in healthy adult volunteers, in which sisunatovir produced statistically significant reductions in viral load and clinical symptoms. ReViral has recently initiated an international multicentre Phase 2 clinical study of sisunatovir in hospitalized infants.
About Respiratory Syncytial Virus (RSV)
RSV is a pathogen that usually causes mild, cold-like symptoms but can lead to severe and life-threatening lower respiratory tract infections, or LRTIs, in high-risk populations, such as infants, toddlers, and young children, immunocompromised patients, and the elderly. RSV constitutes a substantial disease burden. The National Institute of Allergy and Infectious Diseases estimates that, globally, RSV affects approximately 64 million people and causes approximately 160,000 deaths
each year. Globally, there are an estimated 33 million cases of RSV LRTI each year in children younger than five years of age, with about three million of them being hospitalized and approximately 60,000 dying each year from complications associated with the infection.
Source: ReViral Ltd.